Limits...
Role of Bcl-2 -938 C > A polymorphism in susceptibility and prognosis of cancer: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.

No MeSH data available.


Related in: MedlinePlus

Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in five genetic models.(A) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA; (B) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CC; (C) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CA vs CC (D) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CC vs AA+CA; (E) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA+CC.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5384243&req=5

f6: Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in five genetic models.(A) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA; (B) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CC; (C) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CA vs CC (D) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CC vs AA+CA; (E) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA+CC.

Mentions: Fourteen studies evaluating the prognostic value of Bcl-2 -938 C>A polymorphism in cancer were included in our meta-analysis. The results of our meta-analysis suggested that the Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; CA vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97) (Figure 6). Sensitivity analysis was performed and the results didn't show any statistical significant difference when any study was omitted (Supplementary Table S10-Table S14). Begg's funnel plot and Egger's test were performed, and no significant publication bias was found (Supplementary Table S15).


Role of Bcl-2 -938 C > A polymorphism in susceptibility and prognosis of cancer: a meta-analysis
Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in five genetic models.(A) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA; (B) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CC; (C) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CA vs CC (D) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CC vs AA+CA; (E) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA+CC.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5384243&req=5

f6: Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in five genetic models.(A) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA; (B) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CC; (C) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CA vs CC (D) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in CC vs AA+CA; (E) Forest plot of Bcl-2 -938 C>A polymorphism and cancer prognosis in AA vs CA+CC.
Mentions: Fourteen studies evaluating the prognostic value of Bcl-2 -938 C>A polymorphism in cancer were included in our meta-analysis. The results of our meta-analysis suggested that the Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; CA vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97) (Figure 6). Sensitivity analysis was performed and the results didn't show any statistical significant difference when any study was omitted (Supplementary Table S10-Table S14). Begg's funnel plot and Egger's test were performed, and no significant publication bias was found (Supplementary Table S15).

View Article: PubMed Central - PubMed

ABSTRACT

The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00–1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11–1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04–1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11–1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.

No MeSH data available.


Related in: MedlinePlus